Hydrogel nasal spray could cut insulin injections; Soligenix has fast track designation for pediatric Crohn's;

> Many researchers are tackling the puzzle of insulin delivery and how to take the burden of daily injections away from insulin-dependent diabetics. A hydrogel in development could make insulin delivery as simple as a once-a-day nasal spray. Abstract | Article

> CRO Particle Sciences has developed an ocular formulation for its client, Eyeon Therapeutics, to deliver a treatment for dry eye. Press release

> Insmed has completed target enrollment of the Phase III clinical trial of ARIKACE (inhaled liposomal amikacin) in cystic fibrosis patients with pseudomonas lung infections. Press release

> An antibody-drug conjugate targeting prostate cancer cells was well-tolerated in Phase I trials with early signs of activity, and a Phase II trial is under way. Press release

> The FDA has granted Soligenix fast track designation for SGX203 (immediate and delayed-release tablet) for mild-to-moderate pediatric Crohn's disease. Press release

> CellAct Pharma's etoposide prodrug shows signs of activity in advanced cancer Phase I study. Press release

> Colby Pharmaceutical has licensed rights to intra-lymph node delivery technologies from MannKind. Article

And Finally… In an almost Halloween story, a protein-based gel that moves on its own could deliver drugs. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.